ArticlePloS one2016
Remyelination Is Correlated with Regulatory T Cell Induction Following Human Embryoid Body-Derived Neural Precursor Cell Transplantation in a Viral Model of Multiple Sclerosis.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Beyond immune suppression: regenerative programs in regulatory T cells.Cell insight · 2026Review
- Neural Stem/Progenitor Cells Regulate Neuroinflammation: Mechanisms and Therapeutic Applications in Neurological Diseases.International journal of molecular sciences · 2026Review
- OCA-B promotes pathogenic maturation of stem-like CD4+ T cells and autoimmune demyelination.The Journal of clinical investigation · 2025Article
- Brain regulatory T cells.Nature reviews. Immunology · 2024Review
- Research progress of autoimmune diseases based on induced pluripotent stem cells.Frontiers in immunology · 2024Review
- Presentation of Human Neural Stem Cell Antigens Drives Regulatory T Cell Induction.Journal of immunology (Baltimore, Md. : 1950) · 2023Article
- Regulatory T cell therapy for multiple sclerosis: Breaching (blood-brain) barriers.Human vaccines & immunotherapeutics · 2022Review
- Regulatory Cells in Multiple Sclerosis: From Blood to Brain.Biomedicines · 2022Review
- Common Peripheral Immunity Mechanisms in Multiple Sclerosis and Alzheimer's Disease.Frontiers in immunology · 2021Review
- Neurologic Manifestations of COVID-19.Advances in experimental medicine and biology · 2021Article
- Regulatory T cells promote remyelination in the murine experimental autoimmune encephalomyelitis model of multiple sclerosis following human neural stem cell transplant.Neurobiology of disease · 2020Article
- Beneficial and Detrimental Effects of Regulatory T Cells in Neurotropic Virus Infections.International journal of molecular sciences · 2020Review
- Inducing human induced pluripotent stem cell differentiation through embryoid bodies: A practical and stable approach.World journal of stem cells · 2020Review
- Harnessing the Neural Stem Cell Secretome for Regenerative Neuroimmunology.Frontiers in cellular neuroscience · 2020Review
- Concise Review: Human-Animal Neurological Chimeras: Humanized Animals or Human Cells in an Animal?Stem cells (Dayton, Ohio) · 2019Review
- Promoting remyelination through cell transplantation therapies in a model of viral-induced neurodegenerative disease.Developmental dynamics : an official publication of the American Association of Anatomists · 2019Review
- Characterization of a murine mixed neuron-glia model and cellular responses to regulatory T cell-derived factors.Molecular brain · 2018Article
- Fingolimod therapy is not effective in a mouse model of spontaneous autoimmune peripheral polyneuropathy.Scientific reports · 2018Article
- Neural Stem Cell-Based Regenerative Approaches for the Treatment of Multiple Sclerosis.Molecular neurobiology · 2018Review
- Stem Cells as Potential Targets of Polyphenols in Multiple Sclerosis and Alzheimer's Disease.BioMed research international · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
We have recently described sustained clinical recovery associated with dampened neuroinflammation and remyelination following transplantation of neural precursor cells (NPCs) derived from human embryonic stem cells (hESCs) in a viral model of the human demyelinating disease multiple sclerosis. The hNPCs used in that study were derived by a novel direct differentiation method (direct differentiation, DD-NPCs) that resulted in a unique gene expression pattern when compared to hNPCs derived by conventional methods. Since the therapeutic potential of human NPCs may differ greatly depending on the method of derivation and culture, we wanted to determine whether NPCs differentiated using conventional methods would be similarly effective in improving clinical outcome under neuroinflammatory demyelinating conditions. For the current study, we utilized hNPCs differentiated from a human induced pluripotent cell line via an embryoid body intermediate stage (EB-NPCs). Intraspinal transplantation of EB-NPCs into mice infected with the neurotropic JHM strain of mouse hepatitis virus (JHMV) resulted in decreased accumulation of CD4+ T cells in the central nervous system that was concomitant with reduced demyelination at the site of injection. Dampened neuroinflammation and remyelination was correlated with a transient increase in CD4+FOXP3+ regulatory T cells (Tregs) concentrated within the peripheral lymphatics. However, compared to our earlier study, pathological improvements were modest and did not result in significant clinical recovery. We conclude that the genetic signature of NPCs is critical to their effectiveness in this model of viral-induced neurologic disease. These comparisons will be useful for understanding what factors are critical for the sustained clinical improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.